Schering Corporation

Merck Sharp + Dohme Corp.

Other

Schering Corportion

Guowei Zhou

Joseph A Kozlowski

Brian J Lavey

Michael K C Wong

Wensheng Yu

Ling Tong

Bandarpalle B Shankar

De-Yi Yang

Neng-Yang Shih

Dansu Li

Lei Chen

Seong Heon Kim

Kristin E Rosner

M Arshad Siddiqui

Janeta Popovici-Muller

Vinay M Girijavallabhan

Chaoyang Dai

Razia Rizvi

Zhuyan Guo

Peter Orth

Vincent Stewart Madison

Robert Feltz

Judson E Richard

Luke Fire

Aneta Maria Kosinski

Aneta M Micula

Joel G Berger

Wei K Chang

Umar Faruk Mansoor

Richard J Friary

Liping Yang

Youheng Shu

Seong-Heon Kim

William J Greenlee

Andrew William Stamford

Zhaoning Zhu

Brian Alexander McKittrick

Michael W Miller

Xing Dai

Gerald Wayne Shipps, Jr

Pauline C Ting

Sunil Paliwal

Duane E DeMong

Robert D Mazzola, Jr

Tin-Yau Chan

Lianyun Zhao

David Benjamin Belanger

Henry A Vaccaro

Shing-Chun C Wong

Kristen E Rosner

Aneta Maria Kosinzki

Shankar B Bandarpalle

Duane Eugene Demong

Razia K Rizvi

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto. 

Spiro-imidazolone derivatives as glucagon receptor antagonists

This invention relates to compounds of the Formula (I): 

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-&#x3b1; or combinations thereof.

There are disclosed compounds of the formula I: or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.

Cannabinoid receptor ligands

Growing community of inventors

Livingston, NJ, United States of America

Guowei Zhou